Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mind Medicine (MindMed) Inc. - Common Shares
(NQ:
MNMD
)
8.180
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine (MindMed) Inc. - Common Shares
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
New Psychedelics ETF Launches On NYSE Arca
February 02, 2022
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...
Via
Benzinga
Mindset Pharma, Allied Among Top Psychedelic Movers Of Today
February 01, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 15.70% at $0.69
Via
Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
January 31, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 7.89% at $5.33
Via
Benzinga
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
January 30, 2022
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.
Via
Talk Markets
MindMed Successfully Completes Phase 1 Trial Of 18-MC
January 19, 2022
This article was originally published on Microdose...
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 28, 2022
January 28, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 17.86% at $0.57
Via
Benzinga
Bruce Linton's Óskare Capital Announces Strategic Cannabis Investment Partnership
January 27, 2022
Óskare Capital, the life science and deep tech fund owned by renown investor Bruce Linton and Alpha Blue Ocean, a global investment firm, announced on Thursday the formation of a strategic partnership...
Via
Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 27, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49
Via
Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 26, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
MindMed Shares Soar After FDA Approves First Commercial Clinical Trial On LSD In 40 Years
January 26, 2022
MindMed (NASDAQ:MNMD), a drug development company in the p...
Via
Benzinga
51 Biggest Movers From Yesterday
January 26, 2022
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients...
Via
Benzinga
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
January 25, 2022
GAINERS: Mind Medicine (NASDAQ:
Via
Benzinga
BNTX Stock Alert: The Omicron Vaccine News That Has BioNTech Shooting Higher Today
January 25, 2022
BioNTech (BNTX) stock is rising higher on news it and Pfizer (PFE) can test a new Covid-19 vaccine for Omicron in adults.
Via
InvestorPlace
MNMD Stock: The FDA Go-Ahead That Has MindMed Investors Feeling Euphoric Today
January 25, 2022
MindMed (MNMD) stock is getting a buzz today thanks to approval from the FDA to move forward with a clinical trial of MM-120.
Via
InvestorPlace
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Jan. 25, 2022: MSFT, SHOP, ERIC, MNMD, TSLA
January 25, 2022
Today's 5 Stock Ideas: Microsoft (MSFT) - The company reports Q2 earnings today after the close. Shopify (SHOP) - Shares down premarket. Keybanc lowered its price target...
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
January 24, 2022
GAINERS: Field Trip Health (NASDAQ:
Via
Benzinga
Psyched: Eleusis To Go Public Via Merger, New Psychedelics Bills In Utah, Virginia, Kansas And Missouri
January 24, 2022
Psychedelics Legalization Gains Momentum Around The Country: Bills Introduced In Utah, Virginia, Kansas And Missouri A wave of psychede...
Via
Benzinga
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD
January 23, 2022
This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From January 21, 2022
January 21, 2022
GAINERS: GH Research (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
January 20, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
January 19, 2022
GAINERS: Revive Therapeutics (OTC:
Via
Benzinga
Psilocybin and MDMA Get the Green Light for Medical Use in Canada
January 19, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – January 19, 2022 – After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of...
Via
FinancialNewsMedia
Psychedelic Stock Gainers And Losers From January 18, 2022
January 18, 2022
GAINERS: Cybin (AMEX:
Via
Benzinga
MindMed Launches Study Using Monitoring System For Psychedelic Experiences
January 18, 2022
Psychedelics biotech company MindMed (NASDAQ:MNMD) has enr...
Via
Benzinga
Cannabis Movers & Shakers: MindMed, Halo Collective, Item 9, PSYC, Flora Growth
January 10, 2022
Stephen Hurst Steps Down From MindMed's Board Of Directors Psychedelic-focused biotech company Mind Medicine Inc
Via
Benzinga
Psyched: Canada's Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington
January 10, 2022
Canada Opens New Legal Pathways For Access To Treatment With Psilocybin And MDMA In a groundbreaking decision, the Canadian gov...
Via
Benzinga
Pure-Play Marijuana- & Psychedelic Compounds-Based Drug Stocks Index Is Down By 66% From 2021 High
January 09, 2022
There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index is now DOWN -65.9% from its highs in 2021. Here are the details for each of its constituents.
Via
Talk Markets
A Recap of How Psychedelics Fared in 2021
January 07, 2022
Via
Investor Brand Network
MindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine
January 04, 2022
On Tuesday, Mind Medicine Inc. (NASDAQ:MNMD) (NEO: MM...
Via
Benzinga
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?
December 30, 2021
Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for inv...
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.